Cite
HARVARD Citation
Snydman, D. et al. (2018). Antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin. Journal of antimicrobial chemotherapy. pp. 2078-2084. [Online].